---
title: "Incannex Receives A$6.0M R&D Tax Refund, Expects A$11.1M+ in Non-Dilutive Funding"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/289319892.md"
description: "Incannex Healthcare received A$6.04 million in R&D tax incentive proceeds, boosting its cash position. The company expects over A$11.1 million in total non-dilutive funding by late 2026. These funds strengthen the balance sheet without dilution or debt, supporting clinical programs like IHL-42X and PSX-001, as well as a share repurchase program."
datetime: "2026-06-10T11:33:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/289319892.md)
  - [en](https://longbridge.com/en/news/289319892.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/289319892.md)
generator: "portal-rs"
---

# Incannex Receives A$6.0M R&D Tax Refund, Expects A$11.1M+ in Non-Dilutive Funding

**Incannex received A$6.04 million in R&D tax incentive proceeds and expects more than A$11.1 million in non-dilutive funding in 2026.**

**Key Highlights:**

-   Received A$6,039,162.43 under Australia’s R&D Tax Incentive Program, boosting cash position.
-   expects an additional ~A$5.1 million in R&D proceeds later in 2026, bringing total to >A$11.1M.
-   Proceeds are non-dilutive, strengthening balance sheet without issuing shares or taking on debt.
-   Funds provide flexibility to advance clinical programs including IHL-42X and PSX-001.
-   Also supports shareholder-focused capital allocation, including active share repurchase program.

Original SEC Filing: Incannex Healthcare Inc. \[ IXHL \] - 8-K - Jun. 10, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [IXHL.US](https://longbridge.com/en/quote/IXHL.US.md)

## Related News & Research

- [Incannex wins US patent for IHL-42X obstructive sleep apnea treatment, expiry 2040](https://longbridge.com/en/news/298450120.md)
- [Incannex Secures A$5.1M R&D Tax Incentive Refund](https://longbridge.com/en/news/295535573.md)
- [MLYS: Lorundrostat prepares for launch with strong clinical data, parity access strategy, and full funding](https://longbridge.com/en/news/298510829.md)
- [Clarivate report shows Mainland China leads library AI implementation at 28%](https://longbridge.com/en/news/298412143.md)
- [SPTX: Innovative oral neuropsychiatric therapies advance toward pivotal trials, backed by strong leadership](https://longbridge.com/en/news/298485305.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**